Original Article
Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B)

https://doi.org/10.1097/JTO.0b013e31816de276Get rights and content
Under an Elsevier user license
open archive

Purpose

This study was undertaken to explore the response rate of a first-line, three-drug regimen that consisted of bortezomib, paclitaxel, and carboplatin in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, or gastric cardia.

Patients and Methods

Patients with the above diagnosis and acceptable organ function were treated intravenously on a 21-day cycle with the following: bortezomib 1.2 mg/m2 on days 1, 4, and 8; paclitaxel 175 mg/m2 on day 2; and carboplatin with an area under the curve of 6 on day 2. Patients received indefinite treatment unless they manifested tumor progression or severe adverse events. All were monitored for tumor response as well as other clinical outcomes.

Results

The cohort included 35 eligible patients with a median age of 59 years (range, 36–78) and an Eastern Cooperative Oncology Group performance score of 0, 1, and 2 in 60%, 34%, and 6% of patients, respectively. Although this regimen was well tolerated, the tumor response rate was lower than that anticipated at 23% (95% confidence interval: 10%, 40%), thereby prompting premature study closure. There were no complete responses. The median survival for the cohort was 8.9 months (95% confidence interval: 5.9, 12.8).

Conclusion

As prescribed in this trial and for this indication, this regimen does not merit further testing.

Cited by (0)

Disclosure: The authors declare no conflicts of interest.

This study was conducted as a collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic and was supported in part by Public Health Service grants: CA-25224, CA-37404, CA-15083, CA-63848, CA-35195, CA-35090, CA-35269, CA-37417, CA-52654, CA-35267, CA-63849, CA-35113, CA-60276, CA-35119, CA-35103, and CA-35431.

Additional participating institutions include: Siouxland Hematology-Oncology Associates, Sioux City, IA 51105 (Donald B. Wender, MD); Missouri Valley Cancer Consortium, Omaha, NE 68131 (Gamini S. Soori, MD); Mayo Clinic Jacksonville, Jacksonville, FL 32224 (Edith Perez, MD); Duluth CCOP, Duluth, MN 55805 (Daniel A. Nikcevich, MD); Medcenter One Health Systems, Bismarck, ND 58506 (Edward J. Wos, D.O.); Meritcare Hospital CCOP, Fargo, ND 58122 (Preston D. Steen, MD); Upstate Carolina CCOP, Spartanburg, SC 29303 (James D. Bearden, III, MD); Abbott Northwestern Hospital, Minneapolis, MN 55407 (Daniel J. Schneider, MD); Mayo Clinic Scottsdale, Scottsdale, AZ 85259-5404 (Tom R. Fitch, MD); Mobile Infirmary Medical Center, Mobile, AL 36607 (Paul Schwarzenberger, MD).